Top

Published in:

01-09-2006 | News item

VTE risk reflected in US labelling for Ortho Evra

Published in: Reactions Weekly | Issue 1/2006

Excerpt

According to the US FDA, Ortho-McNeil and the FDA have informed healthcare professionals and patients that the prescribing information for Ortho Evra [ethinylestradiol/norelgestromin] has been updated to highlight results of two epidemiology studies that assessed the risk of a serious blood clot among women receiving Ortho Evra versus those using a different oral contraceptive (OC).* …

FDA.Ortho Evra (norelgestromin/ethinyl estradiol). Internet Document: [1 page], 21 Sep 2006. Available from: URL: http://www.fda.gov

Title: VTE risk reflected in US labelling for Ortho Evra
Publication date: 01-09-2006
Publisher: Springer International Publishing
Published in: Reactions Weekly / Issue 1/2006
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.2165/00128415-200611210-00005

Keynote webinar | Spotlight on medication adherence

Springer Medicine

VTE risk reflected in US labelling for Ortho Evra

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2006

Interferon-α

Capecitabine

Filgrastim

Omalizumab

Antibody therapy phase I trial safety remains topical

Domperidone and ketoconazole interaction warning in SA